Education
About Us
Working with TipRanks
Follow Us
Theratechnologies (TSE:TH)
:TH
TH Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.59 - C$4.49
Previous CloseN/A
Volume38.24K
Average Volume (3M)51.06K
Market Cap
C$205.99M
Enterprise ValueC$225.52M
Total Cash (Recent Filing)C$9.92M
Total Debt (Recent Filing)C$43.62M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Oct 09, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding45,980,020
10 Day Avg. Volume35,854
30 Day Avg. Volume51,063
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$4.51Price Target Upside0.56% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Acquisition OfferThe acquisition offer from Future Pak represents a 126% premium to the closing price before the announcement, indicating a significant value proposition for shareholders.
Market OutlookThe price target for Theratechnologies has been increased from $3 to $4, indicating a positive outlook.
Product DevelopmentThe launch of EGRIFTA WR is expected to allow the company to increase sales growth and maintain positive momentum.
Bears Say
Financial Performance2Q25 fully adjusted EPS of ($0.09) missed consensus expectations of ($0.01), which may indicate financial challenges.
Supply DisruptionAn expected one-time reduction in revenue due to a supply disruption resulted in a $10M — $12M decrease for FY25.
Transparency ConcernsTheratechnologies confirmed it does not intend to provide updates or comments on the ongoing negotiations unless required by law, creating a lack of transparency for investors.
Theratechnologies News
TH FAQ
What was Theratechnologies’s price range in the past 12 months?
Theratechnologies lowest stock price was C$1.59 and its highest was C$4.49 in the past 12 months.
What is Theratechnologies’s market cap?
Theratechnologies’s market cap is C$205.99M.
When is Theratechnologies’s upcoming earnings report date?
Theratechnologies’s upcoming earnings report date is Oct 09, 2025 which is in 53 days.
How were Theratechnologies’s earnings last quarter?
Theratechnologies released its earnings results on Jul 09, 2025. The company reported -C$0.124 earnings per share for the quarter, missing the consensus estimate of -C$0.021 by -C$0.103.
Is Theratechnologies overvalued?
According to Wall Street analysts Theratechnologies’s price is currently Undervalued.
Does Theratechnologies pay dividends?
Theratechnologies does not currently pay dividends.
What is Theratechnologies’s EPS estimate?
Theratechnologies’s EPS estimate is 0.02.
How many shares outstanding does Theratechnologies have?
Theratechnologies has 45,980,020 shares outstanding.
What happened to Theratechnologies’s price movement after its last earnings report?
Theratechnologies reported an EPS of -C$0.124 in its last earnings report, missing expectations of -C$0.021. Following the earnings report the stock price went down -0.116%.
Which hedge fund is a major shareholder of Theratechnologies?
Currently, no hedge funds are holding shares in TSE:TH
Theratechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
C$4.51 (0.56% Upside)
C$4.51 (0.56% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.98%
Trailing 12-Months
Company Description
Theratechnologies
Theratechnologies Inc. is a Canadian biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious medical conditions. The company primarily operates in the biotechnology sector, specializing in the research and development of treatments for metabolic and endocrine disorders, with a particular emphasis on human immunodeficiency virus (HIV) and growth hormone deficiencies. Its core product, Trogarzo (ibalizumab-uiyk), is a monoclonal antibody approved for the treatment of HIV-1 in heavily treatment-experienced patients, highlighting the company's commitment to addressing unmet medical needs in complex patient populations.
TH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and new product approval, indicating positive market momentum. However, challenges such as the drug shortage and declining Trogarzo sales were significant concerns. The company's strategic focus on transitioning to the new product formulation and managing operational efficiencies shows resilience.View all TSE:TH earnings summariesTH Stock 12 Month Forecast
Average Price Target
C$4.51
▲(0.56% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
Biosyent
―
HLS Therapeutics Inc
―
Medicure
―
Crescita Therpeutc
―
Ownership Overview
―
Insiders
0.06%
Mutual Funds
<0.01% Other Institutional Investors
99.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---